| 注册
首页|期刊导航|中国药业|停用哌拉西林他唑巴坦后抗菌药物用量及细菌敏感性变化分析

停用哌拉西林他唑巴坦后抗菌药物用量及细菌敏感性变化分析

张瑜 纪莎 郑沁鈊 郑宓 李颖 陈验彬

中国药业Issue(19):55-56,2.
中国药业Issue(19):55-56,2.

停用哌拉西林他唑巴坦后抗菌药物用量及细菌敏感性变化分析

Changes of Antimicrobial Usage Amount and Bacterial Sensitivity before and after Suspending Piperacillin Tazobactam

张瑜 1纪莎 1郑沁鈊 1郑宓 1李颖 1陈验彬2

作者信息

  • 1. 福建中医药大学附属第二人民医院,福建 福州 350003
  • 2. 福建中医药大学药学院,福建 福州 350003
  • 折叠

摘要

Abstract

Objective To observe the changes of the antimicrobial usage amount commonly used to anti-Pseudomonas aeruginosa and the resistance of Gram-negative bacterium before and after suspending Piperacillin Tazobactam, in order to provide the basis for clinical management of antimicrobial agents. Methods The antibacterial resistance test results of Gram-negative bacterium which were based on isolation from inpatients between 2012 and 2013, were analyzed. The usage amount of antibiotics was analyzed in terms of quarters using Defined Daily Dose ( DDD ) and DDDs by the hospital office systems which were commonly used to anti-Pseudomonas aerugi-nosa. Results The resistance rates of Piperacillin Tazobactam decreased significantly due to the suspension of some of Gram-negative bacterium, such as Pseudomonas aeruginosa and Escherichia coli. The resistance rates of some anti-Pseudomonas aeruginosa antimicrobial drugs to Pseudomonas aeruginosa were also decreased significantly, such as Cefoperazone Sulbactam, Meropenem, and so on. At the same time, the DDDs was not effected significantly. Conclusion It may be an effective and feasible measure to suspense some antimicrobial drugs plainly for clinical management of antimicrobial agents, especially for the one which had high resistance rate. It is beneficial to decline of the resistance of targeted bacterium, and has no significant impact on the other antimicrobial usage.

关键词

哌拉西林他唑巴坦/细菌耐药率/用药频度/抗菌药物管理

Key words

piperacillin tazobactam/resistance/DDDs/management of antimicrobial agents

分类

医药卫生

引用本文复制引用

张瑜,纪莎,郑沁鈊,郑宓,李颖,陈验彬..停用哌拉西林他唑巴坦后抗菌药物用量及细菌敏感性变化分析[J].中国药业,2015,(19):55-56,2.

中国药业

1006-4931

访问量0
|
下载量0
段落导航相关论文